News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
Volume11
Issue 9

Regis Technologies Reports Successful FDA Inspection

FDA found no observations during recent inspection of Regis Technologies manufacturing site.

Regis Technologies has announced that no Form 483 observations were issued following a recent 12-day inspection by FDA of the quality and production systems at its Chicago-area facility.  The inspection was a routine quality systems inspection to support Regis’ FDA registration and ongoing manufacture of clinical and commercial APIs, according to a Aug. 25, 2016 company statement.

Regis provides synthesis, separations, and manufacturing services to pharmaceutical and biotechnology companies from its 36,000-sq-ft facility.

The company works with high value intermediates and APIs from process development and scale-up through validation and commercial manufacturing. The company also offers pharmaceutical regulatory support services, and access to its proprietary innovative chromatography products and services.

Source: Regis Technologies

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More